(Updates to add Hong Kong ticker)
Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) unit Shandong Shengdi received regulatory acceptance in China for the marketing application of its HRS-7535 tablets.
The drug is indicated for blood sugar control in patients with type two diabetes mellitus, according to a Wednesday aftermarket filing with the Shanghai bourse.
Shares of the company were up 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.